MARLBOROUGH, Mass., Jan. 07, 2024 (GLOBE NEWSWIRE) — Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced preliminary unaudited revenue for the fourth quarter and full year ended December 31, 2023, and projected year end 2023 cash, cash equivalents, and restricted cash balance, which remain subject to quarter end closing adjustments and are also unaudited.
GlobeNewswire,is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Latest posts by GlobeNewswire (see all)
- Correction From Source: Firefly Neuroscience Achieves Multi-Fold Database, IP Portfolio, and Commercial Footprint Expansion Through Acquisition of Evoke Neuroscience, Inc. - May 5, 2025
- Mats Inc. Reintroduces Itself as A Matter Surfaces Brand as Company Enhances Digital Experience with New Website - May 5, 2025
- Aura Announces Q1 2025 Financial and Operational Results - May 5, 2025
